Benign prostatic hyperplasia: An overview

Urology

Volumn 53, Issue 3 SUPPL. A, 1999, Pages 1-6

  Ziada, Ali ^a   Rosenblum, Mark ^a   Crawford, E David ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; FINASTERIDE; PHENOXYBENZAMINE; PRAZOSIN; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN;

CLINICAL TRIAL; HUMAN; INCIDENCE; LASER COAGULATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATECTOMY; RESIDUAL URINE; REVIEW; TRANSURETHRAL RESECTION; UROFLOWMETRY;

EID: 0033059904     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00532-9     Document Type: Article

References (51)

1. Barry MJ: Epidemiology and natural history of benign prostatic hyperplasia. AUA Update series, vol 12, lesson 2, 1993.
2. Berry S.J., Coffey D.S., Walsh P.C., et al. The development of human benign prostatic hyperplasia with age. J Urol. 132:1984;474-479.
3. Isaacs J.T., Coffey D.S. Etiology and disease process of benign prostatic hyperplasia. Prostate. 2:(suppl):1989;33-50.
4. Ekman P. BPH epidemiology and risk factors. Prostate. 2:(suppl):1989;23-31.
5. Boyle P., McGinn R., Maisonnuve P., et al. Epidemiology of benign prostatic hyperplasia present knowledge and studies needed . Eur Urol. 20:(suppl 2):1991;3-10.
6. Frea B., Annoscia S., Stanta G., et al. Correlation between liver cirrhosis and benign prostatic hyperplasia a morphological study . Urol Res. 15:1987;311-314.
7. Sanda M.G., Doehring C.B., Binkowitz B., et al. Clinical and biological characteristics of familial benign prostatic hyperplasia. J Urol. 157:1997;876-879.
8. Partin A.W., Page W.F., Lee B., et al. Concordance rates for benign prostatic hyperplasia among twins suggests hereditary influence. Urology. 44:1994;646-650.
9. Porta M., Fernandez E., Alonso J., et al. Risk factors for benign prostatic hyperplasia. Am J Epidemiol. 139:1994;114-115.
10. Matzkin H., Cruton S., Simon D. Is there an association between cigarette smoking and gland size in benign prostatic hyperplasia? Prostate. 29:1996;42-45.
11. Partin A.W., Osterling J.E., Epstein J.I., et al. Influence of age and endocrine factors on the volume of benign prostatic hyperplasia. J Urol. 145:1991;405-409.
12. Coffey D.S. The molecular biology, endocrinology, and physiology of the prostate and seminal vesicles. Walsh P.C., Retik A.B., Stamey T.A., Vaughan E.D. Campbell's Urology. 6th edn. 1992;221-301 WB Saunders, Philadelphia.
13. Grayhack J.T. Changes with aging in human seminal vesicle fluid fructose concentration and seminal vesicle weight. J Urol. 86:1961;142.
14. Cunha G.R., Lung B. The importance of stroma in morphogenesis and functional activity of urogenital epithelium. In Vitro. 15:1979;50-71.
15. Cunha G.R., Chung L.W.K., Shannon J.M., et al. Hormone induced morphogenesis and growth role of mesenchymal epithelial interactions . Recent Prog Horm Res. 39:1983;559-598.
16. Steiner M.S. Role of peptide growth factors in the prostate. A review. Urology. 42:1993;99-110.
17. Caine M. The present role of alpha adrenergic blockers in the treatment of benign prostatic hypertrophy. J Urol. 136:1986;1-4.
18. McNeal J.E. Pathology of benign prostatic hyperplasia. Urol Clin North Am. 17:1990;477-486.
19. Bartsch G., Muller H.R., Oberholzer M., et al. Light microscopic stereological analysis of the normal human prostate and of benign prostatic hyperplasia. J Urol. 122:1979;487-491.
20. James S., Chapple C.R., Phillips M.I., et al. Autoradiographic analysis of alpha-adrenoceptors and muscarinic cholinergic receptors in hyperplastic human prostate. J Urol. 142:1989;438-444.
21. Blaivas J.G. Obstructive uropathy in the male. Urol Clin North Am. 23:1996;373-384.
22. Madsen F.A., Bruskewitz R.C. Clinical manifestations of benign prostatic hyperplasia. Urol Clin North Am. 22:1995;291-298.
23. Holtgrewe H.L. Current trends in management of men with lower urinary tract symptoms and benign prostatic hyperplasia. Urology. 51:(suppl 4A):1998;1-7.
24. Lepor H. The pathophysiology of lower urinary tract symptoms in the ageing male population. Br J Urol. 81:(suppl 1):1998;29-33.
25. Caine M., Raz S., Ziegler M. Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck. Br J Urol. 47:1975;193-202.
26. James S., Chapple C.R., Phillips M.I., et al. Autoradiographic analysis of alpha-adrenoceptors and muscarinic cholinergic receptors in hyperplastic human prostate. J Urol. 142:1989;438-444.
27. Hieble J.P., Bylund D.B., Clarke D.E., et al. International Union of Pharmacology. X. Recommendation of nomenclature of alpha-1 adrenoceptors: consensus update. Pharmacol Rev. 47:1995;267-270.
28. Muramatsu I.M., Oshita T., Ohmura S., et al. Pharmacological characterisation of alpha-1 adrenoceptor subtypes in the human prostate functional and binding studies . Br J Urol. 74:1994;572-578.
29. McConnell JD, Barry MJ, Bruskewitz RC, et al: Benign Prostatic Hyperplasia: Diagnosis and Treatment. Clinical Practice Guidelines, No. 8. AHCPR publication No. 94-0582. Rockville, MD, Agency for Health Care Policy and Research, Public Health Service, US Department of Health and Human Services, 1994.
30. Chancellor M.B., Blaivas J.G., Kaplan S.A., et al. Bladder outlet obstruction versus impaired detrusor contraction the role of uroflow . J Urol. 145:1991;810-812.
31. Griffiths D.A. Pressure flow studies of micturition. Urol Clin North Am. 23:1996;279-297.
32. Monda J.M., Barry M.J., Oesterling J.E. Prostate specific antigen cannot distinguish stage T1a (A1) prostate cancer from benign prostatic hyperplasia. J Urol. 151:1994;1291-1295.
33. Tchetgen M.B., Oesterling J.E. The role of prostate specific antigen in the evaluation of benign prostatic hyperplasia. Urol Clin North Am. 22:1995;333-344.
34. Woodrum D.L., Brawer M.K., Partin A.W., et al. Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. J Urol. 159:1998;5-12.
35. Horninger W., Reissigl A., Klocker H., et al. Improvement of specificity in PSA-based screening by using PSA-transition zone density and percent free PSA in addition to total PSA levels. Prostate. 37:1998;133-137.
36. Kurita Y., Terada H., Masuda H., et al. Prostate specific antigen value adjusted for transition zone volume and free PSA (gamma-seminoprotein)/PSA ratio in the diagnosis of prostate cancer in patients with intermediate PSA levels. Br J Urol. 82:1998;224-230.
37. Stoner E. Maintenance of clinical efficacy with finasteride therapy for 24 months in patients with benign prostatic hyperplasia. Arch Intern Med. 154:1994;83-88.
38. Gormley G.J., Stoner E., Bruskewitz R.C., et al. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med. 327:1992;1185-1191.
39. Lepor H., Williford W.O., Barry M.J., et al. The efficacy of terazosin, finasteride or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med. 335:1996;533-539.
40. Andriole G.L., Guess H.A., Epstein J.I., et al. Treatment with finasteride preserves usefulness of prostate specific antigen in the detection of prostate cancer results of randomized, double-blind, placebo-controlled clinical trial . Urology. 52:1998;192-201.
41. Pannek J., Marks L.S., Pearson J.D., et al. Influence of finasteride on free and total serum PSA levels in men with benign prostatic hyperplasia. J Urol. 159:1998;449-453.
42. Chapple C.R., Noble J.G., Milroy E.J. Comparative study of selective alpha-1 adrenoceptor blockade versus surgery in the treatment of prostatic obstruction. Br J Urol. 72:1993;822-825.
43. Chapple C.R. Selective alpha-1 adrenoceptor antagonists in benign prostatic hyperplasia rationale and clinical experience . Eur Urol. 29:1996;129-144.
44. Gillenwater J.Y., Conn R.L., Chrysant S.G., et al. Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension a double-blind, placebo controlled, dose response multicenter study . J Urol. 154:1995;110-115.
45. Andersson K.E., Lepor H., Wyllie M.G. Prostatic alpha-1 adrenoceptors and uroselectivity. Prostate. 30:1997;202-215.
46. Jepsen J.V., Bruskewitz R.C. Recent developments in the surgical management of benign prostatic hyperplasia. Urology. 51:(suppl 4A):1998;23-31.
47. Thomas K.J., Cornaby A.J., Hammadeh M., et al. Transurethral vaporization of the prostate a promising new technique . Br J Urol. 79:1997;186-189.
48. Dixon C.M. Lasers for the treatment of of benign prostatic hyperplasia. Urol Clin North Am. 22:1995;413-422.
49. De la Rosette J.J., D'Ancona F.C., Debruyne F.M.J. Current status of thermotherapy of the prostate. J Urol. 157:1997;430-438.
50. Bruskewitz R., Issa M., Roehrborn C.G., et al. A prospective randomized 1 year clinical trial comparing transurethral needle ablation to transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia. J Urol. 159:1998;1588-1593.
51. Mulligan E.D., Lynch T.H., Mulvin D., et al. High intensity focused ultrasound in the treatment of benign prostatic hyperplasia. Br J Urol. 79:1997;177-180.